{"transactions":[{"id":4629737,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-10-05T20:05:26.000Z","date":"2026-10-01","kind":"exercise","planned":false,"acquired":false,"shares":14475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs become vested over four (4) years with 25% of the shares vesting on October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs become vested over four (4) years with 25% of the shares vesting on October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."}],"balance_after":43425,"derivative":{"underlying":"Common Stock, par value $0.0001","underlying_shares":14475},"source":{"system":"sec-edgar","filing":"0001251779-26-000011","document":"form4-10052026_041006.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000125177926000011/form4-10052026_041006.xml","form_type":"4"}},{"id":4629736,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001","published_at":"2026-10-05T20:05:26.000Z","date":"2026-10-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":4379,"price":2.76,"value":12086.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs."}],"balance_after":49927,"source":{"system":"sec-edgar","filing":"0001251779-26-000011","document":"form4-10052026_041006.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000125177926000011/form4-10052026_041006.xml","form_type":"4"}},{"id":4629735,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001","published_at":"2026-10-05T20:05:26.000Z","date":"2026-10-01","kind":"exercise","planned":false,"acquired":true,"shares":14475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested."}],"balance_after":54306,"source":{"system":"sec-edgar","filing":"0001251779-26-000011","document":"form4-10052026_041006.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000125177926000011/form4-10052026_041006.xml","form_type":"4"}},{"id":698767,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001","published_at":"2026-08-03T20:05:20.000Z","date":"2026-07-31","kind":"grant","planned":false,"acquired":true,"shares":1753,"price":2.414,"value":4231.742,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan (\"ESPP\"). It pertains to the ESPP purchase period from February 1, 2026 through July 31, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 31, 2026."}],"balance_after":39831,"source":{"system":"sec-edgar","filing":"0001251779-26-000009","document":"form4-08032026_040813.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000125177926000009/form4-08032026_040813.xml","form_type":"4"}},{"id":822741,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001","published_at":"2026-04-01T20:05:18.000Z","date":"2026-04-01","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":3.1499,"value":31499.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.1450 to $3.1499, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":38078,"source":{"system":"sec-edgar","filing":"0001251779-26-000007","document":"form4-04012026_040406.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000125177926000007/form4-04012026_040406.xml","form_type":"4"}},{"id":853337,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001","published_at":"2026-03-09T11:05:04.000Z","date":"2026-03-06","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":3.54,"value":17700.0,"ownership":{"direct":true},"balance_after":28078,"source":{"system":"sec-edgar","filing":"0001251779-26-000005","document":"form4-03092026_070301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000125177926000005/form4-03092026_070301.xml","form_type":"4"}},{"id":877042,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-27T21:05:36.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":111000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs become vested over four (4) years with 25% of the shares vesting February 26, 2027, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs become vested over four (4) years with 25% of the shares vesting February 26, 2027, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."}],"balance_after":111000,"derivative":{"underlying":"Common Stock, par value $0.0001","underlying_shares":111000},"source":{"system":"sec-edgar","filing":"0001251779-26-000002","document":"form4-02272026_040231.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000125177926000002/form4-02272026_040231.xml","form_type":"4"}},{"id":877041,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (option to buy)","published_at":"2026-02-27T21:05:36.000Z","date":"2026-02-26","kind":"grant","planned":false,"acquired":true,"shares":259000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on February 26, 2027, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date."}],"balance_after":259000,"derivative":{"exercise_price":4.46,"expiration_date":"2036-02-26","underlying":"Common Stock, par value $0.0001","underlying_shares":259000},"source":{"system":"sec-edgar","filing":"0001251779-26-000002","document":"form4-02272026_040231.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000125177926000002/form4-02272026_040231.xml","form_type":"4"}},{"id":1001843,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-11-12T21:07:21.000Z","date":"2025-11-11","kind":"exercise","planned":false,"acquired":false,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs become vested over four (4) years with 25% of the shares vesting on November 11, 2025, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs become vested over four (4) years with 25% of the shares vesting on November 11, 2025, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."}],"balance_after":56250,"derivative":{"underlying":"Common Stock, par value $0.0001","underlying_shares":18750},"source":{"system":"sec-edgar","filing":"0001251779-25-000006","document":"form4-11122025_091117.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000125177925000006/form4-11122025_091117.xml","form_type":"4"}},{"id":1001842,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001","published_at":"2025-11-12T21:07:21.000Z","date":"2025-11-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":5672,"price":4.28,"value":24276.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs."}],"balance_after":23078,"source":{"system":"sec-edgar","filing":"0001251779-25-000006","document":"form4-11122025_091117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000125177925000006/form4-11122025_091117.xml","form_type":"4"}},{"id":1001841,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001","published_at":"2025-11-12T21:07:21.000Z","date":"2025-11-11","kind":"exercise","planned":false,"acquired":true,"shares":18750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested."}],"balance_after":28750,"source":{"system":"sec-edgar","filing":"0001251779-25-000006","document":"form4-11122025_091117.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000125177925000006/form4-11122025_091117.xml","form_type":"4"}},{"id":1024365,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2025-10-03T20:24:28.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":57900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs become vested over four (4) years with 25% of the shares vesting October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs become vested over four (4) years with 25% of the shares vesting October 1, 2026, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."}],"balance_after":57900,"derivative":{"underlying":"Common Stock, par value $0.0001","underlying_shares":57900},"source":{"system":"sec-edgar","filing":"0001104659-25-096679","document":"tm2527887-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465925096679/tm2527887-3_4seq1.xml","form_type":"4"}},{"id":1024364,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (option to buy)","published_at":"2025-10-03T20:24:28.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":166800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on October 1, 2026, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date."}],"balance_after":166800,"derivative":{"exercise_price":3.87,"expiration_date":"2035-10-01","underlying":"Common Stock, par value $0.0001","underlying_shares":166800},"source":{"system":"sec-edgar","filing":"0001104659-25-096679","document":"tm2527887-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465925096679/tm2527887-3_4seq1.xml","form_type":"4"}},{"id":1205582,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock, par value $0.0001","published_at":"2025-03-14T11:27:34.000Z","date":"2025-03-13","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":5.1996,"value":51996.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.1950 to $5.1997, inclusive. The reporting person undertakes to provide to Altimmune, Inc., any security holder of Altimmune, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001104659-25-023724","document":"tm259169-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465925023724/tm259169-1_4seq1.xml","form_type":"4"}},{"id":1368679,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-11-12T21:50:52.000Z","date":"2024-11-11","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs become vested over four (4) years with 25% of the shares vesting November 11, 2025, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs become vested over four (4) years with 25% of the shares vesting November 11, 2025, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date."}],"balance_after":75000,"derivative":{"underlying":"Common Stock, par value $0.0001","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001104659-24-116882","document":"tm2428121-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465924116882/tm2428121-2_4seq1.xml","form_type":"4"}},{"id":1368678,"issuer":{"id":5349,"kind":"organization","name":"Altimmune, Inc.","symbol":"ALT"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Options (option to buy)","published_at":"2024-11-12T21:50:52.000Z","date":"2024-11-11","kind":"grant","planned":false,"acquired":true,"shares":225000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on November 11, 2025, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date."}],"balance_after":225000,"derivative":{"exercise_price":7.35,"expiration_date":"2034-11-11","underlying":"Common Stock, par value $0.0001","underlying_shares":225000},"source":{"system":"sec-edgar","filing":"0001104659-24-116882","document":"tm2428121-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1326190/000110465924116882/tm2428121-2_4seq1.xml","form_type":"4"}},{"id":1736632,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true,"officer":true,"officer_title":"Former EVP, CFO, & Director"}}],"security":"Common Stock","published_at":"2023-11-17T21:01:39.000Z","date":"2023-11-15","kind":"sale","planned":false,"acquired":false,"shares":50000,"price":0.65,"value":32500.0,"ownership":{"direct":true},"balance_after":55,"source":{"system":"sec-edgar","filing":"0001437749-23-032461","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923032461/rdgdoc.xml","form_type":"4"}},{"id":1849494,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true,"officer":true,"officer_title":"EVP & CFO"}}],"security":"Common Stock","published_at":"2023-06-21T00:15:24.000Z","date":"2023-06-20","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":0.97,"value":48500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average purchase price per share. The shares were purchased in multiple transactions at prices ranging from $0.93 to $0.99. Upon request from the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares of common stock purchased on November 21, 2013, which were previously reported on a Form 4 filed by the Reporting Person on November 22, 2013 but erroneously omitted in subsequent filings."}],"balance_after":50055,"source":{"system":"sec-edgar","filing":"0001437749-23-017896","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923017896/rdgdoc.xml","form_type":"4"}},{"id":1866986,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true,"officer":true,"officer_title":"EVP & CFO"}}],"security":"Stock Option (right to buy)","published_at":"2023-06-05T13:00:29.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":2600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest with respect to 25% on the one year anniversary of June 1, 2023, and the remainder shall vest in equal quarterly installments over the following three years, subject to the reporting person's continued service through each applicable vesting date."}],"balance_after":2600000,"derivative":{"exercise_price":0.92,"expiration_date":"2033-06-01","underlying":"Common Stock","underlying_shares":2600000},"source":{"system":"sec-edgar","filing":"0001437749-23-016569","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923016569/rdgdoc.xml","form_type":"4"}},{"id":1902692,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-05-05T23:36:21.000Z","date":"2023-05-04","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest on a quarterly basis over the next 12 months.  The options were issued at approximately 9:50 a.m. (ET) on May 4, 2023, with an exercise price of $0.662, representing the most recently reported closing stock price on May 3, 2023."}],"balance_after":125000,"derivative":{"exercise_price":0.662,"expiration_date":"2033-05-04","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001437749-23-012872","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774923012872/rdgdoc.xml","form_type":"4"}},{"id":2270259,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2022-05-16T22:19:09.000Z","date":"2022-05-13","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 9:30 a.m. (ET) on May 13, 2022, with an exercise price of $0.93, representing the most recently reported closing stock price on May 12, 2022."}],"balance_after":50000,"derivative":{"exercise_price":0.93,"expiration_date":"2032-05-13","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001437749-22-012709","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774922012709/rdgdoc.xml","form_type":"4"}},{"id":2349889,"issuer":{"id":72536,"kind":"organization","name":"Atai Beckley N.V.","symbol":"ATAI"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2022-03-04T20:56:03.000Z","date":"2022-03-02","kind":"grant","acquired":true,"shares":228000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the underlying shares on March 2, 2023 and as to the remaining underlying shares in 36 substantially equal monthly installments thereafter."}],"balance_after":228000,"derivative":{"exercise_price":5.65,"expiration_date":"2032-03-01","underlying":"Common Shares","underlying_shares":228000},"source":{"system":"sec-edgar","filing":"0000899243-22-009376","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251779/000089924322009376/doc4.xml","form_type":"4"}},{"id":2639321,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2021-07-07T20:29:44.000Z","date":"2021-07-02","kind":"exercise","acquired":false,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These options were granted on May 15, 2020, vested on a quarterly basis over 12 months and expire 10 years from the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"These options were granted on May 15, 2020, vested on a quarterly basis over 12 months and expire 10 years from the grant date."}],"balance_after":0,"derivative":{"exercise_price":1.7,"underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001437749-21-016573","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774921016573/rdgdoc.xml","form_type":"4"}},{"id":2639320,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2021-07-07T20:29:44.000Z","date":"2021-07-02","kind":"exercise","acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These options were granted on May 17, 2019, vested on a quarterly basis over 12 months and expire 10 years from the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"These options were granted on May 17, 2019, vested on a quarterly basis over 12 months and expire 10 years from the grant date."}],"balance_after":0,"derivative":{"exercise_price":2.52,"underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001437749-21-016573","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774921016573/rdgdoc.xml","form_type":"4"}},{"id":2639319,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2021-07-07T20:29:44.000Z","date":"2021-07-02","kind":"exercise","acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options were granted on June 27, 2018, vested on a quarterly basis over 12 months and expire 10 years from the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These options were granted on June 27, 2018, vested on a quarterly basis over 12 months and expire 10 years from the grant date."}],"balance_after":0,"derivative":{"exercise_price":2.38,"underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001437749-21-016573","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774921016573/rdgdoc.xml","form_type":"4"}},{"id":2639318,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2021-07-07T20:29:44.000Z","date":"2021-07-02","kind":"exercise","acquired":false,"shares":4581,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options were granted on May 24, 2017, vested on a quarterly basis over 12 months and expire 10 years from the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These options were granted on May 24, 2017, vested on a quarterly basis over 12 months and expire 10 years from the grant date."}],"balance_after":0,"derivative":{"exercise_price":5.64,"underlying":"Common Stock","underlying_shares":4581},"source":{"system":"sec-edgar","filing":"0001437749-21-016573","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774921016573/rdgdoc.xml","form_type":"4"}},{"id":2639317,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-07-07T20:29:44.000Z","date":"2021-07-02","kind":"sale","acquired":false,"shares":107497,"price":5.58,"value":599833.26,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Reflects the weighted average sale price. The range of prices for such transaction is $5.51 to $5.65. Open market sale transactions were made on the same day at different prices through a trade order executed by a broker-dealer. The reporting person has reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer or a shareholder of the issuer, full information regarding the number of shares sold at each separate price."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001437749-21-016573","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774921016573/rdgdoc.xml","form_type":"4"}},{"id":2639316,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-07-07T20:29:44.000Z","date":"2021-07-02","kind":"tax_withholding","acquired":false,"shares":57084,"price":6.4,"value":365337.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the Nasdaq closing price of the Issuer's common stock on July 01, 2021."}],"balance_after":107497,"source":{"system":"sec-edgar","filing":"0001437749-21-016573","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774921016573/rdgdoc.xml","form_type":"4"}},{"id":2639315,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-07-07T20:29:44.000Z","date":"2021-07-02","kind":"exercise","acquired":true,"shares":70000,"price":1.7,"value":119000.0,"ownership":{"direct":true},"balance_after":164581,"source":{"system":"sec-edgar","filing":"0001437749-21-016573","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774921016573/rdgdoc.xml","form_type":"4"}},{"id":2639314,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-07-07T20:29:44.000Z","date":"2021-07-02","kind":"exercise","acquired":true,"shares":45000,"price":2.52,"value":113400.0,"ownership":{"direct":true},"balance_after":94581,"source":{"system":"sec-edgar","filing":"0001437749-21-016573","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774921016573/rdgdoc.xml","form_type":"4"}},{"id":2639313,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-07-07T20:29:44.000Z","date":"2021-07-02","kind":"exercise","acquired":true,"shares":45000,"price":2.38,"value":107100.0,"ownership":{"direct":true},"balance_after":49581,"source":{"system":"sec-edgar","filing":"0001437749-21-016573","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774921016573/rdgdoc.xml","form_type":"4"}},{"id":2639312,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true}}],"security":"Common Stock","published_at":"2021-07-07T20:29:44.000Z","date":"2021-07-02","kind":"exercise","acquired":true,"shares":4581,"price":5.64,"value":25836.84,"ownership":{"direct":true},"balance_after":4581,"source":{"system":"sec-edgar","filing":"0001437749-21-016573","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774921016573/rdgdoc.xml","form_type":"4"}},{"id":2655674,"issuer":{"id":72536,"kind":"organization","name":"Atai Beckley N.V.","symbol":"ATAI"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Shares","published_at":"2021-06-24T20:15:27.000Z","date":"2021-06-22","kind":"purchase","acquired":true,"shares":4666,"price":15,"value":69990.0,"ownership":{"direct":true},"balance_after":4666,"source":{"system":"sec-edgar","filing":"0000899243-21-025732","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251779/000089924321025732/doc4.xml","form_type":"4"}},{"id":2658544,"issuer":{"id":72536,"kind":"organization","name":"Atai Beckley N.V.","symbol":"ATAI"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2021-06-22T20:20:55.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":67726,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the underlying shares on June 17, 2022, and the remaining vests in 36 equal monthly installments thereafter."}],"balance_after":67726,"derivative":{"exercise_price":15,"expiration_date":"2031-06-17","underlying":"Common Shares","underlying_shares":67726},"source":{"system":"sec-edgar","filing":"0000899243-21-025282","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251779/000089924321025282/doc4.xml","form_type":"4"}},{"id":2708033,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2021-05-18T20:16:41.000Z","date":"2021-05-14","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 4:30 p.m. (ET) on May 14, 2021 with an exercise price of $2.90, representing the most recently reported closing stock price at the time of grant."}],"balance_after":50000,"derivative":{"exercise_price":2.9,"expiration_date":"2031-05-14","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001437749-21-012671","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774921012671/rdgdoc.xml","form_type":"4"}},{"id":3142661,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2020-05-19T18:06:33.000Z","date":"2020-05-15","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 4:30 p.m. (ET) on May 15, 2020 with an exercise price of $1.70, representing the most recently reported closing stock price at the time of grant."}],"balance_after":70000,"derivative":{"exercise_price":1.7,"expiration_date":"2030-05-15","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001437749-20-011264","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774920011264/rdgdoc.xml","form_type":"4"}},{"id":3209292,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"FORMER CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2020-03-16T20:10:15.000Z","date":"2020-03-15","kind":"exercise","acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units issued to the reporting person on January 30, 2019 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units issued to the reporting person on January 30, 2019 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units issued to the reporting person on January 30, 2019 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"As a result of reporting person's separation from the Issuer, 25% of all unvested equity accelerated in accordance with the reporting person's employment agreement and the remaining unvested equity was forfeited."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001415889-20-000755","document":"form4-03162020_040301.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588920000755/form4-03162020_040301.xml","form_type":"4"}},{"id":3209291,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"FORMER CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2020-03-16T20:10:15.000Z","date":"2020-03-15","kind":"tax_withholding","acquired":false,"shares":1086,"price":2.85,"value":3095.1,"ownership":{"direct":true},"balance_after":10431,"source":{"system":"sec-edgar","filing":"0001415889-20-000755","document":"form4-03162020_040301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588920000755/form4-03162020_040301.xml","form_type":"4"}},{"id":3209290,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"FORMER CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2020-03-16T20:10:15.000Z","date":"2020-03-15","kind":"exercise","acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units issued to the reporting person on January 30, 2019 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock."}],"balance_after":11517,"source":{"system":"sec-edgar","filing":"0001415889-20-000755","document":"form4-03162020_040301.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588920000755/form4-03162020_040301.xml","form_type":"4"}},{"id":3228300,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2020-03-04T19:30:15.000Z","date":"2020-01-30","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects the restricted stock units issued to the reporting person on January 30, 2019 which have partially vested and settled for shares of the issuer's common stock.\nThe original Form 4 filed on January 31, 2020 is amended in its entirety by this Form 4 Amendment to provide the: (a) correct date the restricted stock units were first issued to the reporting person; and (b) correct disposition of the derivative securities."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F3","text":"The original  Form 4 filed on January 31, 2020 is amended by this Form 4 Amendment to correctly identify the nature of the transaction of the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects the restricted stock units issued to the reporting person on January 30, 2019 which have partially vested and settled for shares of the issuer's common stock.\nThe original Form 4 filed on January 31, 2020 is amended in its entirety by this Form 4 Amendment to provide the: (a) correct date the restricted stock units were first issued to the reporting person; and (b) correct disposition of the derivative securities."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects the restricted stock units issued to the reporting person on January 30, 2019 which have partially vested and settled for shares of the issuer's common stock.\nThe original Form 4 filed on January 31, 2020 is amended in its entirety by this Form 4 Amendment to provide the: (a) correct date the restricted stock units were first issued to the reporting person; and (b) correct disposition of the derivative securities."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-20-000636","document":"form4a-03042020_020302.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588920000636/form4a-03042020_020302.xml","form_type":"4/A","original_submission_date":"2020-01-31"}},{"id":3228299,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2020-03-04T19:30:15.000Z","date":"2020-01-30","kind":"tax_withholding","acquired":false,"shares":1733,"price":3.91,"value":6776.03,"ownership":{"direct":true},"balance_after":7767,"source":{"system":"sec-edgar","filing":"0001415889-20-000636","document":"form4a-03042020_020302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588920000636/form4a-03042020_020302.xml","form_type":"4/A","original_submission_date":"2020-01-31"}},{"id":3228298,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2020-03-04T19:30:15.000Z","date":"2020-01-30","kind":"exercise","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the restricted stock units issued to the reporting person on January 30, 2019 which have partially vested and settled for shares of the issuer's common stock.\nThe original Form 4 filed on January 31, 2020 is amended in its entirety by this Form 4 Amendment to provide the: (a) correct date the restricted stock units were first issued to the reporting person; and (b) correct disposition of the derivative securities."}],"balance_after":9500,"source":{"system":"sec-edgar","filing":"0001415889-20-000636","document":"form4a-03042020_020302.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588920000636/form4a-03042020_020302.xml","form_type":"4/A","original_submission_date":"2020-01-31"}},{"id":3296896,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2020-01-31T22:26:55.000Z","date":"2020-01-30","kind":"exercise","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The restricted stock units issued to the reporting person on January 30, 2020 have partially vested and settled for shares of the Issuer's common stock."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The restricted stock units issued to the reporting person on January 30, 2020 have partially vested and settled for shares of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The restricted stock units issued to the reporting person on January 30, 2020 have partially vested and settled for shares of the Issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"The remaining restricted stock units will vest ratably each quarter through January 30, 2023, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001415889-20-000201","document":"form4-01312020_020141.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588920000201/form4-01312020_020141.xml","form_type":"4"}},{"id":3296895,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2020-01-31T22:26:55.000Z","date":"2020-01-30","kind":"tax_withholding","acquired":false,"shares":1733,"price":3.91,"value":6776.03,"ownership":{"direct":true},"balance_after":7767,"source":{"system":"sec-edgar","filing":"0001415889-20-000201","document":"form4-01312020_020141.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588920000201/form4-01312020_020141.xml","form_type":"4"}},{"id":3296894,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2020-01-31T22:26:55.000Z","date":"2020-01-30","kind":"exercise","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The restricted stock units issued to the reporting person on January 30, 2020 have partially vested and settled for shares of the Issuer's common stock."}],"balance_after":9500,"source":{"system":"sec-edgar","filing":"0001415889-20-000201","document":"form4-01312020_020141.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588920000201/form4-01312020_020141.xml","form_type":"4"}},{"id":3516849,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2019-05-22T00:07:23.000Z","date":"2019-05-17","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest on a quarterly basis over the next 12 months. Option grant was issued at 9:00 a.m. (ET) on May 17, 2019 with an exercise price of $2.52, representing the most recently reported closing stock price at the time of grant."}],"balance_after":45000,"derivative":{"exercise_price":2.52,"expiration_date":"2029-05-17","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001437749-19-010648","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000143774919010648/rdgdoc.xml","form_type":"4"}},{"id":3677036,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-05T01:10:42.000Z","date":"2019-01-31","kind":"disposition_to_issuer","acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."}],"balance_after":0,"derivative":{"exercise_price":0.6,"expiration_date":"2028-05-14","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001179110-19-001267","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1251779/000117911019001267/edgar.xml","form_type":"4"}},{"id":3677035,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-05T01:10:42.000Z","date":"2019-01-31","kind":"disposition_to_issuer","acquired":false,"shares":58133,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."}],"balance_after":0,"derivative":{"exercise_price":2.38,"expiration_date":"2027-06-08","underlying":"Common Stock","underlying_shares":58133},"source":{"system":"sec-edgar","filing":"0001179110-19-001267","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1251779/000117911019001267/edgar.xml","form_type":"4"}},{"id":3677034,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-05T01:10:42.000Z","date":"2019-01-31","kind":"disposition_to_issuer","acquired":false,"shares":29666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."}],"balance_after":0,"derivative":{"exercise_price":4.98,"expiration_date":"2026-06-15","underlying":"Common Stock","underlying_shares":29666},"source":{"system":"sec-edgar","filing":"0001179110-19-001267","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1251779/000117911019001267/edgar.xml","form_type":"4"}},{"id":3677033,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-05T01:10:42.000Z","date":"2019-01-31","kind":"disposition_to_issuer","acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."}],"balance_after":0,"derivative":{"exercise_price":12.08,"expiration_date":"2025-06-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001179110-19-001267","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1251779/000117911019001267/edgar.xml","form_type":"4"}},{"id":3677032,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-05T01:10:42.000Z","date":"2019-01-31","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."}],"balance_after":0,"derivative":{"exercise_price":5.7,"expiration_date":"2024-09-30","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001179110-19-001267","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1251779/000117911019001267/edgar.xml","form_type":"4"}},{"id":3677031,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-05T01:10:42.000Z","date":"2019-01-31","kind":"disposition_to_issuer","acquired":false,"shares":667,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."}],"balance_after":0,"derivative":{"exercise_price":15,"expiration_date":"2024-06-09","underlying":"Common Stock","underlying_shares":667},"source":{"system":"sec-edgar","filing":"0001179110-19-001267","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1251779/000117911019001267/edgar.xml","form_type":"4"}},{"id":3677030,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-05T01:10:42.000Z","date":"2019-01-31","kind":"disposition_to_issuer","acquired":false,"shares":2083,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the First Amended Joint Plan of Reorganization filed by Egalet Corporation and its subsidiaries under Chapter 11 of the United States Bankruptcy Code (the \"Plan\"), the common stock and other equity interests of Egalet Corporation reported as disposed of herein were cancelled and retired and ceased to exist at the effective time of the Plan."}],"balance_after":0,"derivative":{"exercise_price":12,"expiration_date":"2024-02-04","underlying":"Common Stock","underlying_shares":2083},"source":{"system":"sec-edgar","filing":"0001179110-19-001267","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251779/000117911019001267/edgar.xml","form_type":"4"}},{"id":3681476,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Units","published_at":"2019-02-01T00:49:38.000Z","date":"2019-01-30","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The restricted stock units were issued pursuant to the Issuer's 2018 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units will vest as follows: 25% after first anniversary and ratably each quarter over the next three years thereafter subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Vested shares will be delivered promptly after each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units will vest as follows: 25% after first anniversary and ratably each quarter over the next three years thereafter subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Vested shares will be delivered promptly after each vesting date."}],"balance_after":20000,"derivative":{"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-19-000111","document":"form4-01312019_040123.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588919000111/form4-01312019_040123.xml","form_type":"4"}},{"id":3681475,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Options","published_at":"2019-02-01T00:49:38.000Z","date":"2019-01-30","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on January 30, 2020, and the remainder vests in twelve equal quarterly installments thereafter."}],"balance_after":60000,"derivative":{"exercise_price":11.53,"expiration_date":"2029-01-30","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001415889-19-000111","document":"form4-01312019_040123.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000141588919000111/form4-01312019_040123.xml","form_type":"4"}},{"id":3880459,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-29T20:02:11.000Z","date":"2018-06-27","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest on a quarterly basis over the next 12 months."}],"balance_after":45000,"derivative":{"exercise_price":2.38,"expiration_date":"2028-06-27","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001615774-18-005994","document":"s111128_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000161577418005994/s111128_form4.xml","form_type":"4"}},{"id":3932588,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-15T20:20:53.000Z","date":"2018-05-14","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options to purchase shares of common stock vest 100% on the day prior to the date of the Corporation's annual meeting of stockholders to be held in 2019 subject to the director's continued service through the vesting date."}],"balance_after":75000,"derivative":{"exercise_price":0.6,"expiration_date":"2028-05-14","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001179110-18-006813","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251779/000117911018006813/edgar.xml","form_type":"4"}},{"id":3983230,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-03-26T21:11:59.000Z","date":"2018-03-23","kind":"purchase","acquired":true,"shares":4500,"price":8.56,"value":38520.0,"ownership":{"direct":true},"balance_after":4500,"source":{"system":"sec-edgar","filing":"0001209191-18-021643","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118021643/doc4.xml","form_type":"4"}},{"id":4037448,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-02-23T21:17:25.000Z","date":"2017-12-20","kind":"grant","acquired":true,"shares":399266,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The initial Form 4 filed on December 22, 2017, by the Reporting Person inadvertently overstated the exercise price of the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable over a four-year period commencing on December 20, 2017, with one fourth of the shares of common stock underlying the options vesting on December 20, 2018, and the remainder vests in twelve equal quarterly installments thereafter."}],"balance_after":399266,"derivative":{"exercise_price":6,"expiration_date":"2027-12-19","underlying":"Common Stock","underlying_shares":399266},"source":{"system":"sec-edgar","filing":"0001209191-18-012960","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000120919118012960/doc4a.xml","form_type":"4/A","original_submission_date":"2017-12-22"}},{"id":4122636,"issuer":{"id":7180,"kind":"organization","name":"Eloxx Pharmaceuticals, Inc."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-22T19:50:58.000Z","date":"2017-12-20","kind":"grant","acquired":true,"shares":399266,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable over a four-year period commencing on December 20, 2017, with one fourth of the shares of common stock underlying the options vesting on December 20, 2018, and the remainder vests in twelve equal quarterly installments thereafter."}],"balance_after":399266,"derivative":{"exercise_price":7,"expiration_date":"2027-12-20","underlying":"Common Stock","underlying_shares":399266},"source":{"system":"sec-edgar","filing":"0001144204-17-065040","document":"tv482001_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1035354/000114420417065040/tv482001_4.xml","form_type":"4"}},{"id":4285263,"issuer":{"id":148990,"kind":"organization","name":"Zyla Life Sciences","symbol":"ZCOR"},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-12T20:34:21.000Z","date":"2017-06-08","kind":"grant","acquired":true,"shares":58133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options to purchase shares of common stock vest 100% on the day prior to the date of the Corporation's annual meeting of stockholders to be held in 2018 subject to the director's continued service through the vesting date."}],"balance_after":58133,"derivative":{"exercise_price":2.38,"expiration_date":"2027-06-08","underlying":"Common Stock","underlying_shares":58133},"source":{"system":"sec-edgar","filing":"0001179110-17-008915","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1251779/000117911017008915/edgar.xml","form_type":"4"}},{"id":4302950,"issuer":{"id":7556,"kind":"organization","name":"ATOSSA THERAPEUTICS, INC."},"owners":[{"id":27161,"kind":"person","name":"WEAVER GREGORY L","position":1,"cik":"0001251779","reported_name":"WEAVER GREGORY L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-05-26T17:55:33.000Z","date":"2017-05-24","kind":"grant","acquired":true,"shares":54949,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options shall vest on a quarterly basis over the next 12 months."}],"balance_after":69917,"derivative":{"exercise_price":0.47,"expiration_date":"2027-05-24","underlying":"Common Stock","underlying_shares":54949},"source":{"system":"sec-edgar","filing":"0001615774-17-002749","document":"s106366_form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1488039/000161577417002749/s106366_form4.xml","form_type":"4"}}]}